What is HC Wainwright's Estimate for Arvinas Q3 Earnings?

Arvinas, Inc. (NASDAQ:ARVN - Free Report) - Equities researchers at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for shares of Arvinas in a research report issued to clients and investors on Wednesday, February 12th. HC Wainwright analyst A. Fein forecasts that the company will post earnings of ($0.54) per share for the quarter. HC Wainwright has a "Buy" rating and a $87.00 price objective on the stock. The consensus estimate for Arvinas' current full-year earnings is ($3.81) per share. HC Wainwright also issued estimates for Arvinas' FY2025 earnings at ($2.13) EPS, FY2026 earnings at ($3.54) EPS, FY2027 earnings at ($2.54) EPS and FY2028 earnings at $2.77 EPS.

Other research analysts have also issued research reports about the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arvinas in a report on Friday, February 7th. BMO Capital Markets reiterated an "outperform" rating and set a $82.00 price target (down previously from $88.00) on shares of Arvinas in a report on Wednesday, February 12th. BTIG Research began coverage on Arvinas in a research report on Tuesday, December 10th. They set a "buy" rating and a $69.00 target price on the stock. Guggenheim reiterated a "buy" rating and issued a $57.00 target price on shares of Arvinas in a report on Wednesday, February 12th. Finally, Barclays cut their price target on Arvinas from $48.00 to $32.00 and set an "overweight" rating on the stock in a report on Monday, February 3rd. Thirteen equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $60.00.

Arvinas Stock Performance

Shares of Arvinas stock traded down $0.17 on Monday, reaching $18.37. 1,023,363 shares of the stock were exchanged, compared to its average volume of 947,244. The firm has a market cap of $1.26 billion, a PE ratio of -6.63 and a beta of 1.88. The firm's 50 day moving average is $18.55 and its 200-day moving average is $23.02. Arvinas has a one year low of $16.61 and a one year high of $51.51.

Arvinas (NASDAQ:ARVN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same quarter in the previous year, the business earned ($2.53) earnings per share.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. JPMorgan Chase & Co. raised its holdings in shares of Arvinas by 18.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company's stock worth $57,371,000 after acquiring an additional 367,343 shares during the last quarter. Baker BROS. Advisors LP purchased a new stake in shares of Arvinas in the third quarter worth approximately $9,989,000. SG Americas Securities LLC raised its stake in shares of Arvinas by 228.8% in the fourth quarter. SG Americas Securities LLC now owns 32,424 shares of the company's stock worth $622,000 after purchasing an additional 22,564 shares during the last quarter. Wasatch Advisors LP lifted its holdings in shares of Arvinas by 58.3% in the third quarter. Wasatch Advisors LP now owns 435,943 shares of the company's stock valued at $10,737,000 after purchasing an additional 160,510 shares in the last quarter. Finally, Barclays PLC boosted its holdings in Arvinas by 198.9% during the 3rd quarter. Barclays PLC now owns 121,699 shares of the company's stock worth $2,998,000 after acquiring an additional 80,984 shares during the last quarter. 95.19% of the stock is owned by institutional investors.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.